DOCSLIB.ORG

Pandemic H1N1 'Swine Flu'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pandemic H1N1 'Swine Flu' Pandemic H1N1 ‘Swine flu’ FACTFILE Pandemic H1N1 ‘Swine flu’ • A novel influenza A H1N1 virus emerged from Mexico in April 2009 and spread so rapidly that the World Health Organization declared a global flu pandemic on 11 June. • Symptoms can include fever, fatigue, lack of appetite, coughing and sore throat and, in about one quarter of cases, vomiting and diarrhoea. • There were two peaks of infection in the UK, the first during the summer months and the second smaller peak over the traditional winter influenza season. In the post-pandemic period the virus reappeared, behaving as a seasonal strain. Influenza overview quickly through the population development of a novel adapted Influenza viruses in human across the globe irrespective of the strain. As the human population may populations are usually classified season. not have encountered the virus before, as seasonal or pandemic. Seasonal Typically, influenza viruses it has little or no immunity (antibodies) influenza usually causes yearly predominately circulate in birds; rarely to the novel strain. Such processes epidemics in the old, the very young they can infect and genetically adapt probably allowed the pandemics in and those with underlying medical to replicate well in other animal hosts. 1918, 1957 and 1968 to occur. Each conditions, and is often associated with Additionally, different viral strains can pandemic was caused by a different cold periods in temperate regions. An infect a single host and exchange that subtype of influenza, named for the influenza virus becomes classified as adapted genetic material, a process outer spike proteins of the virus (H1N1, pandemic when a novel strain emerges made easier as the genome is separated H2N2 and H3N2, respectively), which from an animal reservoir and is not only into eight segments, allowing mixing are the sections of the virus most able to infect humans but also spreads (reassortment) to occur and lead to recognised by the host antibodies. 2 Factfile: H1N1 | www.microbiologysociety.org Coloured transmission electron micrograph of H1N1 swine flu virus particles from the April 2009 outbreak, which originated in Mexico City, Mexico. The 2009 H1N1 strain spread rapidly between them, and thus illness and/or death; however, as the The WHO named the new 2009 virus cause the 2009 pandemic. Since 2009, virus spread the number of severe influenza A(H1N1)pdm09, but it was this virus has repeatedly transmitted cases in the infected population termed ‘swine flu’ in the media as the back into pigs from humans. Other decreased. Unlike H5N1 (‘bird flu’ in virus displayed genetic similarities with reassorted viruses have transmitted the media) and other highly pathogenic existing pig viruses. This influenza virus from pigs to humans, but they have not influenza viruses, the pandemic H1N1 was the result of the reassortment of been able to transmit between humans strain does not normally spread outside four different bird (avian) viruses that as well as the A(H1N1)pdm09 virus. the respiratory tract; this is usually a had adapted to use pigs (and a human trait associated with a milder seasonal intermediary) as hosts and mixing Who is affected? disease. While there were severe and pots for several years, hence the name When the virus was originally detected, fatal cases requiring hospitalisation, ‘swine flu’. The new A(H1N1)pdm09 virus the news from Mexico was alarming – most cases of A(H1N1)pdm09 flu in the was able to transmit to humans and many of the cases resulted in critical UK were mild. Factfile: H1N1 | www.microbiologysociety.org 3 Treating illness (Relenza™) and peramivir. These antivirals work by blocking the release of the virus from infected cells by inhibiting a viral enzyme. Influenza strains that were resistant to oseltamivir were first identified several years ago. Oseltamivir-resistant A(H1N1)pdm09 influenza had been reported in <1% of cases in the last 6 years, according to Public Health England. Oseltamivir resistance most often occurs in patients who are immunosuppressed, who tend to clear the virus more slowly from the body. Pharmacist holding packets of TamifluTM (oseltamivir) capsules. Other drugs are being The normal recommended treatment inside human cells or blocking the developed; some such as favipiravir for flu for healthy individuals is bed spread of virus from one infected cell to target the viral replication machinery rest and a high fluid intake. Remedies the next. whereas others specifically seek to containing paracetamol or ibuprofen In certain situations (as inhibit the virus by temporarily will help ease symptoms such as a happened early in the pandemic), blocking specific host proteins that high temperature and muscle pain. antivirals can be given to prevent flu the virus needs to replicate or by Asprin is not recommended for in healthy people who are exposed to manipulating specific aspects of children. Antibiotics are NOT effective the virus (prophylactic treatment). The the host’s immune system. Neither against viruses such as influenza A(H1N1)pdm09 strain has shown to favipiravir nor peramivir are, as yet, and should only be prescribed to be sensitive to antiviral medications licensed for influenza treatment in treat confirmed secondary bacterial oseltamivir (Tamiflu™), zanamivir the UK. infections, which can lead to bacterial pneumonia. Oseltamivir (Tamiflu) Zanamivir (Relenza) Patients who are deemed to be at Adults, pregnant high risk (e.g. pregnant women, those Adults, pregnant women Safe for use in: women, children and with pre-existing medical conditions and children over 5 babies and young children) from pandemic or seasonal flu strains are prescribed Method of administration: Oral Inhaled antiviral medication. This must be taken quickly to be effective, ideally within Formulation: Capsule or liquid Dry powder 12–48 hours of onset of symptoms. One 75 mg capsule Two 5 mg doses of powder Adult dosage: Antiviral medications do not cure per day for five days per day for five days illness but they can reduce the length of symptoms by about a day and usually Child dosage: Weight-related Same as adult dosage lessen their severity. Antivirals work Common side effects: Nausea and vomiting None by blocking the virus from replicating 4 Factfile: H1N1 | www.microbiologysociety.org As observed in previous pandemics, Phase Containment phase Treatment phase the majority of the cases were in young people under 25, although a reasonable Aim Limit spread of infection Minimise impact of pandemic proportion of middle-aged people were also affected; this is in contrast Suspected cases tested to Suspected cases no longer tested to seasonal flu that predominantly confirm H1N1 infection to confirm H1N1 infection affects the elderly, who have a less Antiviral medication given to Fast access to antivirals through robust immune system. However, when confirmed cases National Pandemic Flu Service they are infected, some groups have Action an increased risk of suffering from taken Schools closed (where medical H1N1 vaccine production complications from an A(H1N1)pdm09 advice deemed it appropriate) fast-tracked infection. These include the elderly, people with long-term health conditions Prophylactic treatment of close Licensed H1N1 vaccine offered including asthma, diabetes and obesity, contacts of infected people with to vulnerable groups in order of women in the later stages of pregnancy antiviral medication priority and those with weakened immune systems. with peak seasonal flu season at with vaccine manufacturers were in the end of December/beginning of place to quickly develop a vaccine The spread of disease January; however, the number of new against a new strain of flu. Vaccines, H1N1 infection spread rapidly in June H1N1 cases did not reach the figures even when fast-tracked, take time to and July 2009 as the majority of people that were expected. The following make. The first vaccine doses in the UK were naïve to the virus and therefore influenza season, 2010–2011, saw a were not ready until 21 October 2009; had no antibodies to it. The number of sustained number of A(H1N1)pdm09 so, when the A(H1N1)pdm09 strain new cases each week started to double infections in the young and middle- first emerged, public health authorities and peaked at 100,000 per week in aged, and a higher-than-expected focused their efforts on containing the England. In October, the number of new level of hospitalisation and critical spread of infection. As more and more cases per week started to increase care patients. The seasonal H1N1 and people became infected, effort was again and a second, smaller peak of H3N2 viruses were supplanted by the centred upon treating the disease to infection occurred. It was predicted newly emerged virus. However, since minimise the impact of the pandemic. that the second wave would coincide 2010–2011, both A(H1N1)pdm09 and A/ The UK officially moved from a H3N2 have circulated as the seasonal containment phase to a treatment phase strains, with A(H1N1)pdm09 dominating on 2 July 2009. the first season, then H3N2 the following To ease the mounting pressure on two winters; currently each virus GPs, the National Pandemic Flu Service predominates on alternate flu seasons. was launched in the UK at the end of Influenza B viruses have co-circulated July. This service provided an online throughout. or telephone diagnosis of a patient’s symptoms and gave them quick access Dealing with the pandemic to antiviral medication if necessary. Most countries, including the UK, Patients were advised to nominate a ‘flu had flu preparedness plans in place. friend’ to collect the medication for them In Britain, before a pandemic alert was to further limit the spread of infection. issued by the WHO, preparations were Much was learnt from the 2009 already underway. Enough antiviral pandemic; the preparedness plans have medication was stockpiled to treat half been modified for each stage of the Illustration of a global influenza pandemic.
Load more

Recommended publications
  • Avian Influenza “Bird Flu”
    AVIAN FLU CONCERNS ESCALATE WORLDWIDE Louise Shimmel Avian influenza (“bird flu” as it is sometimes called in the press) is making its way into the news almost daily and causing worry among global health authorities, including the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and the National Institute of Allergy and Infectious Diseases (NIAID). Avian influenzas are not new; they come in many types with widely varying levels of disease-causing capability. Definition: Influenza type A viruses, which include human and avian flu viruses, are categorized by H and N components, which denote specific types of proteins on their surface. The H component governs the ability of the virus to bind to and enter cells, which become virus-making factories. The N component governs the release of the newly made viruses from the animal host cell." [Reuters alertnet, 16 Nov 2005, edited.] There are 16 different HA subtypes and 9 different NA in type A influenza viruses. "There are only three known A subtypes of human flu viruses (H1N1, H1N2, and H3N2). When discussing “bird flu” we are talking about the influenza A subtypes chiefly found in birds. They do not usually infect humans, even though we know they can. [Fact Sheet, Avian Influenza, William T. Ferrier, DVM - prepared for falconers.] The virus making headlines is a specific subtype-H5N1-but there is more than one form of H5N1, specifically high- and low-pathogenic strains. The high-pathogenic form of H5N1 is the one in Asia that is causing global concern. There has been a low-pathogenic form of H5N1 found in migrating wild birds in Canada this fall, which is no cause for alarm.
    [Show full text]
  • Influenza: Pigs, People & Public Health
    National Pork Board | 800-456-7675 | pork.org Public Health Fact Sheet Influenza: Pigs, People & Public Health Authors: Amy L. Vincent, DVM, PhD, USDA-ARS National Animal Disease Center; Marie R. Culhane, DVM, PhD, College of Veterinary Medicine, University of Minnesota; Christopher W. Olsen, DVM PhD, School of Veterinary Medicine and School of Medicine and Public Health, University of Wisconsin-Madison. Reviewers: Jeff B. Bender, DVM MS, University of Minnesota; Andrew Bowman, DVM PhD, The Ohio State University; Todd Davis, PhD, CDC; Ellen Kasari, DVM MS, USDA; Heather Fowler, VMD PhD MPH, National Pork Board Influenza A viruses (IAV) were first isolated from swine in the United States in 1930. Since that time, they remain an economically important cause of respiratory disease in pigs throughout the world and a public health risk. The clinical signs/symptoms of influenza in pigs and people are remarkably similar, with influenza-like illness (ILI) consisting of fever, lethargy, lack of appetite and coughing promi- nent in both species. Influenza viruses can be directly transmitted from pigs to people as “zoonotic” disease agents (pathogens that are transmitted from animals to humans or shared by animals and humans) and cause human infections. Conversely, influenza viruses from people can also infect and cause disease in pigs. These interspecies infections are most likely to occur when people and pigs are in close proximity with one another, such as during livestock exhibits at fairs, live animal markets, swine production barns, and slaughterhouses. Finally, pigs can serve as intermediaries in the generation of novel reassorted influenza viruses since they are also susceptible to infection with avian influenza viruses.
    [Show full text]
  • Drug Name Peramivir Brand Name(S)
    Antimicrobial Stewardship Program Drug Name Peramivir Brand Name(s) Rapivab Drug Class Neuraminidase inhibitor Restriction level Restricted to Infectious Diseases and Pulmonology/Critical Care Accepted Indications Management of Influenza A or B in patients with the following: Strict NPO (no NGT/OGT/G-tube/J-tube) Concerns about poor gut absorption (i.e. ileus) Unacceptable Uses Management of Influenza A or B in a patient who can tolerate oral therapy whether by mouth, G-tube, or J-tube Side Effects Insomnia (3%), Diarrhea (8%), Hyperglycemia (serum glucose >160 mg/dL, 5%), Neutropenia (8%), Increased serum ALT/AST (3%), Increased CPK, 4% Pregnancy Class C Dosing Adult: 600 mg IV once* Renal dosing: - CrCl 30-50 mL/min: 200 mg dose IV once* - CrCl 15-29 mL/min: 100 mg dose IV once* - CrCl <10 mL/min or ESRD on HD: 100 mg dose once after HD‡ Pediatrics: - Children: 2-12 years: 12 mg/kg as a single dose; maximum 600mg - Adolescents ≥13 years: Refer to adult dosing Renal dosing: Infants, Children, and Adolescents <18 years: Note: Dosage adjustment based on renal function estimated using the Schwartz equation. CrCl ≥50 mL/minute/1.73 m2: No adjustment necessary CrCl 31 to 49 mL/minute/1.73 m2: 29 to 30 days of life: 1.5 mg/kg/dose once daily for 5 to 10 days 31 to 90 days of life: 2 mg/kg/dose once daily for 5 to 10 days 91 to 180 days of life: 2.5 mg/kg/dose once daily for 5 to 10 days 181 days of life through 5 years: 3 mg/kg/dose once daily for 5 to 10 days; maximum dose: 150 mg/dose 6 to 17 years: 2.5 mg/kg/dose once daily for 5 to 10
    [Show full text]
  • Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
    Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza Aeron Hurt WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia www.influenzacentre.org NA inhibitor antiviral drugs Top view of NA NA inhibitor NA enzyme active site The NA inhibitors Oseltamivir Zanamivir - Oral, IV(?) - Inhaled, IV(?) - Global - Global Peramivir Laninamivir -IV - Inhaled (single) - Japan, - Japan S.Korea, China, US The NA inhibitors Oseltamivir Zanamivir - Oral, IV(?) - Inhaled, IV(?) - Global - Global • Came on the market in many countries in 2000 after clinical studies had been conducted among influenza virus–infected patients with uncomplicated illness. • Oseltamivir is market leader ……due to ease of oral administration • Use for seasonal influenza mainly in Japan and US • With human infections of highly pathogenic influenza A(H5N1) virus from 2003 with a high case‐fatality risks of >50%, governments began to consider antiviral drug administration as a key component of their pandemic response • suitable vaccines would not be available Stockpiling for a pandemic • Oseltamivir was simpler (oral) administration than zanamivir (inhalation) and because of systemic effect of oseltamivir was expected to be appropriate for treatment of highly pathogenic viruses • Oseltamivir was suddenly in high demand! • Roche had warned that need to stockpile to guarantee availability • Since 2005, governments of middle‐income and high‐income countries around the world have spent billions of dollars (estimated) stockpiling oseltamivir (US Gov. Accounting Office). 2009 A(H1N1)pdm09 pandemic • The first pandemic of the 21st century occurred unexpectedly in 2009 after the global spread of a novel virus—influenza A(H1N1)pdm09—of swine (rather than avian) origin.
    [Show full text]
  • Antiviral Agents Active Against Influenza a Viruses
    REVIEWS Antiviral agents active against influenza A viruses Erik De Clercq Abstract | The recent outbreaks of avian influenza A (H5N1) virus, its expanding geographic distribution and its ability to transfer to humans and cause severe infection have raised serious concerns about the measures available to control an avian or human pandemic of influenza A. In anticipation of such a pandemic, several preventive and therapeutic strategies have been proposed, including the stockpiling of antiviral drugs, in particular the neuraminidase inhibitors oseltamivir (Tamiflu; Roche) and zanamivir (Relenza; GlaxoSmithKline). This article reviews agents that have been shown to have activity against influenza A viruses and discusses their therapeutic potential, and also describes emerging strategies for targeting these viruses. HXNY In the face of the persistent threat of human influenza A into the interior of the virus particles (virions) within In the naming system for (H3N2, H1N1) and B infections, the outbreaks of avian endosomes, a process that is needed for the uncoating virus strains, H refers to influenza (H5N1) in Southeast Asia, and the potential of to occur. The H+ ions are imported through the M2 haemagglutinin and N a new human or avian influenza A variant to unleash a (matrix 2) channels10; the transmembrane domain of to neuraminidase. pandemic, there is much concern about the shortage in the M2 protein, with the amino-acid residues facing both the number and supply of effective anti-influenza- the ion-conducting pore, is shown in FIG. 3a (REF. 11). virus agents1–4. There are, in principle, two mechanisms Amantadine has been postulated to block the interior by which pandemic influenza could originate: first, by channel within the tetrameric M2 helix bundle12.
    [Show full text]
  • Treatment and Prevention of Pandemic H1N1 Influenza
    Annals of Global Health VOL. 81, NO. 5, 2015 ª 2015 The Authors. Published by Elsevier Inc. ISSN 2214-9996 on behalf of Icahn School of Medicine at Mount Sinai http://dx.doi.org/10.1016/j.aogh.2015.08.014 REVIEW Treatment and Prevention of Pandemic H1N1 Influenza Suresh Rewar, Dashrath Mirdha, Prahlad Rewar Rajasthan, India Abstract BACKGROUND Swine influenza is a respiratory infection common to pigs worldwide caused by type Ainfluenza viruses, principally subtypes H1N1, H1N2, H2N1, H3N1, H3N2, and H2N3. Swine influenza viruses also can cause moderate to severe illness in humans and affect persons of all age groups. People in close contact with swine are at especially high risk. Until recently, epidemiological study of influenza was limited to resource-rich countries. The World Health Organization declared an H1N1 pandemic on June 11, 2009, after more than 70 countries reported 30,000 cases of H1N1 infection. In 2015, incidence of swine influenza increased substantially to reach a 5-year high. In India in 2015, 10,000 cases of swine influenza were reported with 774 deaths. METHODS The Centers for Disease Control and Prevention recommend real-time polymerase chain reaction as the method of choice for diagnosing H1N1. Antiviral drugs are the mainstay of clinical treatment of swine influenza and can make the illness milder and enable the patient to feel better faster. FINDINGS Antiviral drugs are most effective when they are started within the first 48 hours after the clinical signs begin, although they also may be used in severe or high-risk cases first seen after this time.
    [Show full text]
  • Influenza Vaccine Directive
    FAQS: INFLUENZA VACCINE DIRECTIVE FLU VACCINE UPDATES: Flu shots are now required for all staff working in healthcare settings in Alameda County and Berkeley, as recently ordered in a joint mandate by public health officers for Alameda County. This new mandate notes that with the flu season overlapping the COVID-19 pandemic, the risk is higher for health systems to be overwhelmed by patients with critical respiratory illness. Although there is no vaccine yet for COVID-19, the flu shot remains a safe and effective way to minimize the impacts of flu season and thousands of related doctor and hospital visits. Under Alameda County’s new order, all workers in healthcare settings must receive a flu vaccine to help protect themselves, teammates, patients and the wider community. Within our organization, all employees who work in Alameda County and have direct patient contact, must receive a flu shot no later than December 3, 2020. The new mandate specifies that you may only decline a flu shot if you provide a signed certification from your primary care provider stating that you have a medical condition that makes it unsafe to receive the flu vaccine. Masking is not an acceptable alternative to receiving the flu shot. If you haven’t yet received your flu shot, and you work in an Epic Care location within Alameda County, you must receive a flu vaccine on or before December 3, 2020. Flu vaccines are available at your local pharmacy, your doctor’s office, or Epic Care (while supplies last). If you are unable to obtain a flu vaccine through Epic Care, and you instead receive it from a different pharmacy or doctor’s office, the out of pocket cost of the vaccine will be reimbursed to you with a valid receipt for payment.
    [Show full text]
  • Influenza Virus-Related Critical Illness: Prevention, Diagnosis, Treatment Eric J
    Chow et al. Critical Care (2019) 23:214 https://doi.org/10.1186/s13054-019-2491-9 REVIEW Open Access Influenza virus-related critical illness: prevention, diagnosis, treatment Eric J. Chow1,2, Joshua D. Doyle1,2 and Timothy M. Uyeki2* Abstract Annual seasonal influenza epidemics of variable severity result in significant morbidity and mortality in the United States (U.S.) and worldwide. In temperate climate countries, including the U.S., influenza activity peaks during the winter months. Annual influenza vaccination is recommended for all persons in the U.S. aged 6 months and older, and among those at increased risk for influenza-related complications in other parts of the world (e.g. young children, elderly). Observational studies have reported effectiveness of influenza vaccination to reduce the risks of severe disease requiring hospitalization, intensive care unit admission, and death. A diagnosis of influenza should be considered in critically ill patients admitted with complications such as exacerbation of underlying chronic comorbidities, community-acquired pneumonia, and respiratory failure during influenza season. Molecular tests are recommended for influenza testing of respiratory specimens in hospitalized patients. Antigen detection assays are not recommended in critically ill patients because of lower sensitivity; negative results of these tests should not be used to make clinical decisions, and respiratory specimens should be tested for influenza by molecular assays. Because critically ill patients with lower respiratory tract disease may have cleared influenza virus in the upper respiratory tract, but have prolonged influenza viral replication in the lower respiratory tract, an endotracheal aspirate (preferentially) or bronchoalveolar lavage fluid specimen (if collected for other diagnostic purposes) should be tested by molecular assay for detection of influenza viruses.
    [Show full text]
  • Novel H1N1 Influenza Updated Key Points June 11, 2009 • On
    Novel H1N1 Influenza Updated Key Points June 11, 2009 • On June 11, 2009, the World Health Organization (WHO) raised the worldwide pandemic alert level to Phase 6. • Designation of this phase indicates that a global pandemic is underway. • There are now community level outbreaks ongoing in other parts of the world. • State and international borders don’t matter at this point. The bottom line is that this new virus is among us all. • While U.S. influenza surveillance systems indicate that overall flu activity is decreasing in the United States, novel H1N1 outbreaks are ongoing in different parts of the U.S., in some cases with intense activity. • In the United States, this virus has been spreading efficiently from person-to-person since April and, as we have been saying for some time, we do expect that we will see more cases, more hospitalizations and more deaths from this virus. • Because there is already widespread novel H1N1 disease in the United States, the WHO Phase 6 declaration does not change what the United States is currently doing to keep people healthy and protected from the virus. • Thus there is no change to CDC’s recommendations for individuals and communities. • WHO’s decision to raise the pandemic alert level to Phase 6 is a reflection of epidemiological changes in other parts of the world and not a reflection of any change in the novel H1N1 virus or associated illness. • At this time, most of the people who have become ill with novel H1N1 in the United States have not become seriously ill and have recovered without hospitalization.
    [Show full text]
  • Chapter 19 Influenza
    Chapter 19: Influenza October 2020 19 Influenza Influenza The disease Influenza is an acute viral infection of the respiratory tract. There are three types of influenza virus: A, B and C. Influenza A and influenza B are responsible for most clinical illness. Influenza is highly infectious with a usual incubation period of one to three days. The disease is characterised by the sudden onset of fever, chills, headache, myalgia and extreme fatigue. Other common symptoms include a dry cough, sore throat and stuffy nose. For otherwise healthy individuals, influenza is an unpleasant but usually self-limiting disease with recovery usually within two to seven days. The illness may be complicated by (and may present as) bronchitis, secondary bacterial pneumonia or, in children, otitis media. Influenza can be complicated more unusually by meningitis, encephalitis or meningoencephalitis. The risk of serious illness from influenza is higher amongst children under six months of age (Poehling et al., 2006; Ampofo et al., 2006; Coffin et al., 2007; Zhou et al, 2012), older people (Thompson et al., 2003 and 2004; Zhou et al, 2012) and those with underlying health conditions such as respiratory or cardiac disease, chronic neurological conditions, or immunosuppression and pregnant women (Neuzil et al., 1998; O’Brien et al., 2004; Nicoll et al., 2008 and Pebody et al., 2010). Influenza during pregnancy may also be associated with perinatal mortality, prematurity, smaller neonatal size and lower birth weight (Pierce et al., 2011; Mendez-Figueroa et al., 2011). Although primary influenza pneumonia is a rare complication that may occur at any age and carries a high case fatality rate (Barker and Mullooly, 1982), it was seen more frequently during the 2009 pandemic and the following influenza season.
    [Show full text]
  • Questions & Answers on Influenza
    101 Questions & Answers on Influenza101 101 Questions & Answers Prof. Dr. A.D.M.E. (Ab) Osterhaus is David De Pooter is working at Link Inc on professor of virology at Erasmus Medical since 2003, the Antwerp (Belgium) based Centre Rotterdam, and professor of communication consultancy agency, Environmental Virology at the Utrecht specialised in strategic communication University. Fascinated by the ingenious and social marketing. Link Inc is working ways viruses circumvent the immune with the European Scientific working Influenza system of their hosts to multiply and Group on Influenza (ESWI) since 1998 and spread, Osterhaus started his quest at the is taking care of the positioning of the interface of virology and immunology. He group, the strategy and the implementa­ Ab Osterhaus quickly translated new insights in this tion of the strategy by developing complex field to applications in animal and targeted communication tools. In this human vaccinology. In addition, he started capacity, David De Pooter is a professional David De Pooter his work on virus discovery, not only writer on medical topics and a communi­ focussing on the identification of a series cation manager of ESWI. As such he has of animal viruses, but also of new human established a fruitful and long standing viruses. collaboration with Prof Ab Osterhaus. (www.linkinc.be) 101 Questions & Answers on Influenza 101 101 Questions & Answers on Influenza Ab Osterhaus David De Pooter Elsevier, Maarssen © Elsevier, Maarssen 2009 Design: Studio Bassa, Culemborg Elsevier is an imprint of Reed Business bv, PO Box 1110, 3600 BC Maarssen, The Netherlands. To order: Elsevier Gezondheidszorg, Marketing dept., Antwoordnummer 2594 (freepost), 3600 VB Maarssen, The Netherlands.
    [Show full text]
  • Influenza: Diagnosis and Treatment
    Influenza: Diagnosis and Treatment David Y. Gaitonde, MD; Cpt. Faith C. Moore, USA, MC; and Maj. Mackenzie K. Morgan, USA, MC Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia Influenza is an acute viral respiratory infection that causes significant morbidity and mortality worldwide. Three types of influ- enza cause disease in humans. Influenza A is the type most responsible for causing pandemics because of its high susceptibility to antigenic variation. Influenza is highly contagious, and the hallmark of infection is abrupt onset of fever, cough, chills or sweats, myalgias, and malaise. For most patients in the outpatient setting, the diagnosis is made clinically, and laboratory con- firmation is not necessary. Laboratory testing may be useful in hospitalized patients with suspected influenza and in patients for whom a confirmed diagnosis will change treatment decisions. Rapid molecular assays are the preferred diagnostic tests because they can be done at the point of care, are highly accurate, and have fast results. Treatment with one of four approved anti-influenza drugs may be considered if the patient presents within 48 hours of symptom onset. The benefit of treatment is greatest when antiviral therapy is started within 24 hours of symptom onset. These drugs decrease the duration of illness by about 24 hours in otherwise healthy patients and may decrease the risk of serious complications. No anti-influenza drug has been proven superior. Annual influenza vaccination is recommended for all people six months and older who do not have contraindications. (Am Fam Physician. 2019; 100:online. Copyright © 2019 American Academy of Family Physicians.) Published online November 11, 2019 BEST PRACTICES IN INFECTIOUS DISEASE Influenza is an acute respiratory infection caused by a negative-strand RNA virus of the Orthomyxoviridae fam- Recommendations from the Choosing ily.
    [Show full text]